A total of 8361 patients were treated with piperacillin–tazobactam between January 2003 and June 2014; 131 (1.57%) had a documented ADR attributed to the drug. In 10 of the 131 (7.6% ...

Antimicrobial CAP treatment costs at UPMC are 2 to 3 times higher than at other similar institutions without a demonstrated benefit in clinical outcomes. These higher costs are driven by ...

Piperacillin is the third most common antibiotic to induce hemolytic anemia, after cefotetan and ceftriaxone. Studies have shown that patients treated with piperacillin should be evaluated for ...

The first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), has been launched in major European markets by Hospira. The treatment received a positive opinion from the European ...